$27.33+0.18 (+0.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Arcutis Biotherapeutics (ARQT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
1 figure withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~367.3%/yr (FY22→FY25), net margin −4.3%. Worth your attention in FY25: Share count (+157.5%) and Capex step-up ($686.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲91.3%
376.1
FY22→FY25CAGR +367.3%/yr
Net income ($M)▲88.5%
−16.1
FY21→FY25CAGR —
Free cash flow ($M)▲94.4%
−6.3
capex stepped upCAGR —
Diluted EPS▲88.8%
−0.13
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+157.5%
49.4mn → 127.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$686.0K
▲380% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-4¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -4.3% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 508,681.0 | 376,072.0 | 196,542.0 | 59,606.0 | 3,686.0 | 0.0 | ▲91.3% | +367.3% (22→25) |
Cost of revenue | 44,871.0 | 36,695.0 | 19,128.0 | 4,987.0 | 754.0 | 0.0 | ▲91.8% | +265.1% (22→25) |
Gross profit | 463,810.0 | 339,377.0 | 177,414.0 | 54,619.0 | 2,932.0 | 0.0 | ▲91.3% | +387.3% (22→25) |
Research & development | 93,855.0 | 77,051.0 | 76,420.0 | 110,575.0 | 182,435.0 | 145,558.0 | ▲0.8% | −14.7% |
Selling, general & admin | 334,792.0 | 274,553.0 | 229,391.0 | 185,145.0 | 122,124.0 | 60,971.0 | ▲19.7% | +45.7% |
Total operating expenses | 428,647.0 | 351,604.0 | 305,811.0 | 295,720.0 | 304,559.0 | 206,529.0 | ▲15.0% | +14.2% |
Operating incomefeeds ROC rank | 35,163.0 | −12,227.0 | −128,397.0 | −241,101.0 | −301,627.0 | −206,529.0 | ▲90.5% | — |
Other income, net | −4,359.0 | −2,743.0 | −10,995.0 | −17,926.0 | −9,831.0 | 173.0 | — | — |
Pretax income | 30,804.0 | −14,970.0 | −139,392.0 | −259,027.0 | −311,458.0 | −206,356.0 | ▲89.3% | — |
Income tax | 894.0 | 1,171.0 | 647.0 | 3,113.0 | 0.0 | — | ▲81.0% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 29,910.0 | −16,141.0 | −140,039.0 | −262,140.0 | −311,458.0 | −206,356.0 | ▲88.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.22 | −0.13 | −1.16 | −3.78 | −5.66 | −4.18 | ▲88.8% | — |
Diluted shares (mn) | 136.84 | 127.23 | 120.96 | 69.31 | 55.03 | 49.41 | ▲5.2% | +26.7% |
| Margins | ||||||||
Gross margin87th pct in Healthcare | 91.2% | 90.2% | 90.3% | 91.6% | 79.5% | — | ▼0.0pp | +10.7pp |
Operating margin | 6.9% | −3.3% | −65.3% | −404.5% | −8183.0% | — | ▲62.1pp | +8179.8pp |
Net margin58th pct in Healthcare | 5.9% | −4.3% | −71.3% | −439.8% | −8449.8% | — | ▲67.0pp | +8445.5pp |
† TTM = trailing four quarters through 2026-09-30.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Arcutis Biotherapeutics' revenue last fiscal year?
Arcutis Biotherapeutics reported revenue of $376.1M in fiscal 2025, up 91.3% from fiscal 2024.
What was Arcutis Biotherapeutics' net income?
Arcutis Biotherapeutics reported net income of −$16.1M in fiscal 2025, a net margin of −4.3%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

